Repositioning of Anti-Inflammatory Drugs for the Treatment of Cervical Cancer Sub-Types.

ABSTRACT: Cervical cancer is the fourth most commonly diagnosed cancer worldwide and, in almost all cases is caused by infection with highly oncogenic Human Papillomaviruses (HPVs). On the other hand, inflammation is one of the hallmarks of cancer research. Here, we focused on inflammatory proteins that classify cervical cancer patients by considering individual differences between cancer patients in contrast to conventional treatments. We repurposed anti-inflammatory drugs for therapy of HPV-16 and HPV-18 infected groups, separately. In this study, we employed systems biology approaches to unveil the diagnostic and treatment options from a precision medicine perspective by delineating differential inflammation-associated biomarkers associated with carcinogenesis for both subtypes. We performed a me

SUBMITTER: Kori M 

PROVIDER: S-EPMC9234276 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature